Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine. FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome The FDA has approved the first cell-based gene therapy for Wiskott-Aldrich syndrome, marking a major milestone for patients with this rare and life-threatening genetic condition.

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.   FDA Approves Targeted Therapy for Relapsed CLL/SLL The U.S. Food and Drug Administration granted traditional approval for a targeted therapy for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphom

Introduction Elranatamab-BCMM is a humanized bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting cytotoxic activity against multiple myeloma cells (1). In phase 2 MagnetisMM-3, subcutaneous step-up dosing followed by weekly and then biweekly schedules achieved deep responses with

Introduction Venous thromboembolism (VTE)—encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a major cause of preventable morbidity and mortality worldwide. Although direct oral anticoagulants (DOACs) and vitamin K antagonists are highly effective for most patients, a small subset continues to experience recurrent thromboti

Introduction Elranatamab-BCMM is a bispecific antibody targeting B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting immune cytotoxicity to eliminate multiple myeloma cells (1). Its subcutaneous administration and step-up dosing schedule are designed to mitigate cytokine release syndrome (CRS) while allowing o

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  Novel Bispecific Antibody Shows Major Follicular Lymphoma Benefit The FDA has approved a novel T-cell-engaging bispecific antibody for adults with relapsed or refractory follicular lymphoma, in combination with standard immunotherapy and

Introduction Acute venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a leading cause of cardiovascular morbidity and mortality, warranting prompt and effective anticoagulation. Traditional management with enoxaparin followed by warfarin has demonstrated efficacy but requires parenteral administration, routine

Introduction (1) Atypical haemolytic uraemic syndrome (atypical HUS) is a rare complement-mediated thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA), and progressive renal injury (1). Complement pathway dysregulation caused by acquired or familial abnormalities in complement factor H (CFH), com

Introduction Thrombotic microangiopathy (TMA) is a rare but potentially life-threatening complication that may occur following autologous stem cell transplantation (ASCT) (1). TMA is characterized by microvascular thrombosis, hemolytic anemia, and thrombocytopenia, often leading to kidney (renal) dysfunction (1). Although thrombotic microangiopathy